[Anticoagulant treatment in myocardial infarct].
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001777:Blood Coagulation; D005164:Factor IX / Q000378:metabolism; D005165:Factor V / Q000378:metabolism; D005167:Factor VII / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D010958:Plasminogen / Q000378:metabolism; D013997:Time Factors
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D005165:Factor V; D005167:Factor VII; D005164:Factor IX; D010958:Plasminogen; D006493:Heparin; D005341:Fibrinolysin
Przeciwzakrzepowe leczenie zawału serca.